LDL and statins: the real evidence behind the numbers

For decades, mainstream medicine has presented LDL cholesterol as the primary driver of cardiovascular disease. But the evidence supporting that narrative is weaker than the headlines suggest. Dr. David Diamond, a neuroscientist with more than 46 years of published research, has spent the last 27 years examining the real relationship between LDL, statins, and cardiac risk. His conclusions challenge some of the most established clinical guidelines.

The relative risk trap

When statin trials report a 30% reduction in cardiovascular risk, they are reporting relative risk, not absolute risk. If 3% of the control group had a heart attack and 2% of the treated group did, the absolute difference is 1%, but expressed as relative risk the benefit appears to be 33%. This statistical framing makes statin benefits look considerably larger than they are and explains why many physicians overestimate them.

Dr. Diamond's personal case

Diamond has had LDL close to 200 mg/dL for more than 20 years. He takes no statins, has had no heart attacks or strokes, trains five days a week, and teaches at the University of South Florida. However, 27 years ago his metabolic profile was alarming: triglycerides between 700 and 1,000 mg/dL and HDL so low that his ratio was 25 to 1, a level considered severely high risk.

The solution was not to medicate his LDL but to drastically reduce carbohydrates. Bringing daily intake down to 50 to 100 grams lowered triglycerides to around 150 mg/dL and improved the ratio from 25:1 to roughly 3:1. LDL remained elevated, but Diamond argues that in a metabolically healthy context, high LDL does not translate to greater risk.

LDL is not all the same

LDL is not a single marker. Small, dense LDL particles are the ones that oxidize and contribute to arterial plaque formation. Large, buoyant LDL particles, which predominate in metabolically healthy people on a low-carbohydrate diet, behave very differently. Measuring total LDL without distinguishing between subtypes is, according to Diamond, a clinically misleading oversimplification.

The markers that actually matter

Current guidelines focus on LDL and total cholesterol, but Diamond points to a set of markers with stronger evidence:

Triglycerides: elevated levels are one of the most robust cardiovascular risk factors and respond directly to diet quality.
Fasting insulin: a better predictor of metabolic risk than hemoglobin A1C, yet rarely requested in routine checkups.
Fibrinogen and clotting factors: Diamond, along with collaborators Ben Bikman and Paul Mason, published a 250-reference review arguing that excess clotting, not LDL, is the primary mechanism behind fatal heart attacks. Stress, anger, and high blood sugar chronically activate the clotting cascade.
Blood pressure and inflammation: markers directly tied to real cardiac risk.

Statins: when they are and are not warranted

Diamond does not claim that statins are never justified. His position is that in metabolically healthy people with high LDL, especially in the context of a low-carbohydrate diet, the evidence of benefit is minimal and drug treatment is not warranted. The absolute benefit documented in clinical trials is frequently below 2% and is concentrated in people already diagnosed with cardiovascular disease, not in primary prevention.

What to ask for in a blood panel

For a meaningful cardiovascular assessment, Diamond recommends requesting beyond the standard lipid panel:

Fasting insulin (not just A1C)
Baseline fibrinogen
Triglycerides and triglyceride/HDL ratio
Complete blood count and inflammation (high-sensitivity CRP)
For those with familial hypercholesterolemia, consider a coagulation factor panel

Final thoughts

The debate about LDL and statins is not between science and denial. It is, in Diamond's own framing, between those who read the evidence carefully and those who follow guidelines uncritically. The relevant question is not whether your LDL is high, but whether your overall metabolic profile, including triglycerides, insulin, inflammation, and clotting factors, suggests real risk.